226 related articles for article (PubMed ID: 37807733)
1. [Diagnostic efficacy of prostate cancer using targeted biopsy with 6-core systematic biopsy for patients with PI-RADS 5].
Liu Y; Yuan CW; Wu JY; Shen Q; Xiao JX; Zhao Z; Wang XY; Li XS; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):812-817. PubMed ID: 37807733
[TBL] [Abstract][Full Text] [Related]
2. A clinical available decision support scheme for optimizing prostate biopsy based on mpMRI.
Hou Y; Jiang KW; Zhang J; Bao ML; Shi HB; Qu JR; Cheng G; Zhang YD
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):727-734. PubMed ID: 35067674
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Accuracy of MRI-Ultrasound Fusion Targeted Biopsy Based on PI-RADS v2.1 Category in Transition/Peripheral Zone of the Prostate.
Liu Y; Wang S; Xu G; Zhou B; Zhang Y; Ye B; Xiang L; Zhang Y; Xu H
J Magn Reson Imaging; 2023 Sep; 58(3):709-717. PubMed ID: 36773016
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy.
Oderda M; Albisinni S; Benamran D; Calleris G; Ciccariello M; Dematteis A; Diamand R; Descotes JL; Fiard G; Forte V; Giacobbe A; Marquis A; Marra G; Messas A; Muto G; Peltier A; Rius L; Simone G; Roumeguere T; Faletti R; Gontero P
Prostate; 2023 Feb; 83(2):162-168. PubMed ID: 36259316
[TBL] [Abstract][Full Text] [Related]
6. Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer.
Stabile A; Dell'Oglio P; Soligo M; De Cobelli F; Gandaglia G; Fossati N; Esposito A; Brembilla G; Karnes RJ; Montorsi F; Briganti A
Eur Urol Oncol; 2021 Aug; 4(4):594-600. PubMed ID: 31204312
[TBL] [Abstract][Full Text] [Related]
7. Detection of clinically significant prostate cancer by transperineal multiparametric magnetic resonance imaging-ultrasound fusion targeted prostate biopsy in smaller prostates.
Dahl DM; Kim MM; Wu S; Lin SX; Crotty RK; Cornejo KM; Harisinghani MG; Feldman AS; Wu CL
Urol Oncol; 2022 Oct; 40(10):451.e9-451.e14. PubMed ID: 36008257
[TBL] [Abstract][Full Text] [Related]
8. Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy.
Freifeld Y; Xi Y; Passoni N; Woldu S; Hornberger B; Goldberg K; Bagrodia A; Raj G; Margulis V; Cadeddu JA; Lotan Y; Francis F; Pedrosa I; G Roehrborn C; Costa DN
Urol Oncol; 2019 Jan; 37(1):57-62. PubMed ID: 30446460
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of multiparametric MRI- and microultrasound-targeted biopsy in biopsy-naïve patients with a PI-RADS 5 lesion: a single-institutional study.
Avolio PP; Fasulo V; Sanchez-Salas R; Maffei D; Frego N; Lazzeri M; Paciotti M; Saita A; Hurle R; Guazzoni G; Casale P; Buffi NM; Lughezzani G
World J Urol; 2023 Sep; 41(9):2335-2342. PubMed ID: 37418017
[TBL] [Abstract][Full Text] [Related]
10. Targeted Biopsy With Reduced Number of Cores: Optimal Sampling Scheme in Patients Undergoing Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Prostate Biopsy.
Shen WW; Cui LG; Ran WQ; Sun Y; Jiang J; Pei XL; Chen W
Ultrasound Med Biol; 2020 May; 46(5):1197-1207. PubMed ID: 32107089
[TBL] [Abstract][Full Text] [Related]
11. Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series.
Stabile A; Barletta F; Motterle G; Pellegrino F; Sorce G; Mazzone E; Scuderi S; Cirulli GO; Cucchiara V; Esposito A; Gandaglia G; Fossati N; De Cobelli F; Montorsi F; Karnes RJ; Briganti A
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1137-1142. PubMed ID: 33941867
[TBL] [Abstract][Full Text] [Related]
12. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
13. Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database.
Barletta F; Mazzone E; Stabile A; Scuderi S; Brembilla G; de Angelis M; Cirulli GO; Cucchiara V; Gandaglia G; Karnes RJ; Roupret M; De Cobelli F; Montorsi F; Briganti A
World J Urol; 2022 Nov; 40(11):2683-2688. PubMed ID: 36149448
[TBL] [Abstract][Full Text] [Related]
14. Detection of clinically significant prostate cancer in biopsy-naïve men: direct comparison of systematic biopsy, multiparametric MRI- and contrast-ultrasound-dispersion imaging-targeted biopsy.
Mannaerts CK; Engelbrecht MRW; Postema AW; van Kollenburg RAA; Hoeks CMA; Savci-Heijink CD; Van Sloun RJG; Wildeboer RR; De Reijke TM; Mischi M; Wijkstra H
BJU Int; 2020 Oct; 126(4):481-493. PubMed ID: 32315112
[TBL] [Abstract][Full Text] [Related]
15. The combination of targeted and systematic prostate biopsies is the best protocol for the detection of clinically significant prostate cancer.
Fourcade A; Payrard C; Tissot V; Perrouin-Verbe MA; Demany N; Serey-Effeil S; Callerot P; Coquet JB; Doucet L; Deruelle C; Joulin V; Nonent M; Fournier G; Valeri A
Scand J Urol; 2018 Jun; 52(3):174-179. PubMed ID: 29463177
[TBL] [Abstract][Full Text] [Related]
16. Comparison of prostate cancer detection rates between magnetic resonance imaging-targeted biopsy and transrectal ultrasound-guided biopsy according to Prostate Imaging Reporting and Data System in patients with PSA ≥4 ng/mL: a systematic review and meta-analysis.
Zhu K; Qin Z; Xue J; Miao C; Tian Y; Liu S; Zhu S; Gu Q; Hou C; Xu A; Yang J; Wang Z
Transl Androl Urol; 2019 Dec; 8(6):741-753. PubMed ID: 32038971
[TBL] [Abstract][Full Text] [Related]
17. A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection.
Wajswol E; Winoker JS; Anastos H; Falagario U; Okhawere K; Martini A; Treacy PJ; Voutsinas N; Knauer CJ; Sfakianos JP; Lewis SC; Taouli BA; Rastinehad AR
BJU Int; 2020 Apr; 125(4):531-540. PubMed ID: 31762182
[TBL] [Abstract][Full Text] [Related]
18. Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
Kachanov M; Leyh-Bannurah SR; Roberts MJ; Sauer M; Beyersdorff D; Boiko S; Maurer T; Steuber T; Graefen M; Budäus L
J Urol; 2022 Feb; 207(2):333-340. PubMed ID: 34555925
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the optimal strategy in men with a single unilateral suspicious lesion on MRI undergoing transperineal MRI/ultrasound fusion prostate biopsy.
Yusim I; Mazor E; Frumkin E; Jabareen M; Hefer B; Elsaraya N; Li S; Rouvinov K; Novack V; Mabjeesh NJ
Prostate; 2023 Sep; 83(13):1255-1262. PubMed ID: 37263774
[TBL] [Abstract][Full Text] [Related]
20. Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.
Deniffel D; Perlis N; Ghai S; Girgis S; Healy GM; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA
Eur Radiol; 2022 Nov; 32(11):7544-7554. PubMed ID: 35507051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]